Cardinal Health Posts Steady Revenue Growth in Q3
Cardinal Health, known for its strong presence in the healthcare supply chain, reported impressive third-quarter fiscal year 2025 results. The company’s revenue remained stable at $54.9 billion, while it showcased a significant 19% revenue increase when excluding the impact of a prior customer contract expiration.
Operating Earnings and Earnings Per Share Highlights
In terms of financial performance, the company’s GAAP operating earnings reached $730 million, translating to a GAAP diluted earnings per share (EPS) of $2.10. Conversely, Cardinal Health's non-GAAP operating earnings surged by 21% to $807 million, driven by robust segment profit growth across all operating segments, leading to a non-GAAP diluted EPS increase of 13% to $2.35.
Revised Fiscal 2025 Guidance
In light of its recent performance, Cardinal Health has raised and narrowed its fiscal year 2025 non-GAAP EPS guidance to a range of $8.05 to $8.15, up from a previous forecast of $7.85 to $8.00. This optimistic outlook reflects the anticipated profit growth in its Pharmaceutical and Specialty Solutions segment, which is now projected to grow by 11.5% to 12.5%. The Other segment's profit growth expectation has also been revised upward to 16% to 18%, benefitting from a more substantial organic performance and the completed acquisition of the Advanced Diabetes Supply Group.
Segment Performance Overview
Pharmaceutical and Specialty Solutions Segment
The third-quarter results for the Pharmaceutical and Specialty Solutions segment showed a revenue of $50.4 billion. This was impacted minimally by the customer contract expiration, showcasing a healthy growth trajectory with contributions from brand and specialty pharmaceuticals.
Global Medical Products and Distribution
The Global Medical Products and Distribution segment reported a revenue increase of 2%, totaling $3.2 billion, fueled by a greater volume from existing customers. Segment profits soared by 77%, reaching $39 million, driven by successful cost optimization initiatives.
Cardinal's Recent Developments
Recently, Cardinal Health has continued its expansion strategy, with GI Alliance announcing its entry into the urology specialty therapeutic area. This move aims to strengthen Cardinal Health’s multi-specialty management service organization. Moreover, Cardinal Health executed an acquisition of Advanced Diabetes Supply Group, enhancing its at-Home Solutions capabilities.
Leadership Changes
In governance, Cardinal Health has appointed two new independent directors with extensive experience in leading corporations. The new directors are Robert Musslewhite and Sudhakar Ramakrishna, further diversifying the company’s leadership base.
Investor Engagement and Future Outlook
The company will host a webcast to delve deeper into these results and future prospects. Investors can access this informative session for insights into Cardinal Health’s trajectory and how it plans to navigate the evolving healthcare landscape.
Frequently Asked Questions
What was Cardinal Health's revenue for the third quarter?
Cardinal Health reported a steady revenue of $54.9 billion in Q3.
How did the GAAP operating earnings compare to the previous year?
The GAAP operating earnings reached $730 million, marking a substantial increase in profitability.
What is the new EPS guidance for fiscal year 2025?
The revised non-GAAP EPS guidance for fiscal year 2025 is between $8.05 and $8.15.
What significant changes occurred in Cardinal Health's leadership?
Cardinal Health appointed two new independent directors, enhancing its leadership team.
How is the company positioning itself for future growth?
Cardinal Health is expanding into new markets and enhancing capabilities through strategic acquisitions and initiatives.
